A synthetic heptapeptide analog of tuftsin, researched chiefly as an anxiolytic and nootropic, prescribed in Russia.
Approved in Russia only, as a prescription anxiolytic/nootropic (usually intranasal). Not approved by FDA or EMA — research-use / gray-market in the US and EU.
Also known as: TP-7, tuftsin analog
Modulates GABAergic and monoaminergic (serotonin/dopamine) neurotransmission and upregulates hippocampal BDNF. Thought to inhibit enkephalin degradation, stabilising endogenous regulatory peptides, producing anxiolytic effects without benzodiazepine-like sedation or dependence in preclinical models.
Selank is a synthetic heptapeptide analog of the immune peptide tuftsin, researched as a non-sedating anxiolytic acting via GABAergic and monoaminergic modulation, enkephalin metabolism and BDNF. Small Russian trials reported anxiety reduction comparable to benzodiazepines such as medazepam and phenazepam, without the sedation, tolerance or dependence. However, these studies are small, single-country, often open or non-blinded, and have not been independently replicated to Western RCT standards. There is no large Western phase 3 data and no FDA/EMA review. Promising but unconfirmed.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Reported as generally well tolerated, with a favourable profile versus benzodiazepines (no notable sedation or dependence). But long-term and large-scale safety data are lacking, and adverse effects are poorly characterised outside small studies.
Semax — the other Russian ACTH-derived peptide, paired as 'calm plus focus'. Selank targets anxiety while Semax targets cognition; both are claimed to raise BDNF, which is the usual rationale.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Versus benzodiazepines, Selank is researched as producing comparable anxiolysis without sedation, tolerance or withdrawal. Versus Semax, it is oriented toward anxiety and GABAergic modulation rather than cognition.
No. It is approved only in Russia; US and EU status is research-use with no regulatory approval.
No. Small Russian trials suggest comparable anxiolysis, but the evidence is not independently replicated to Western standards.
Available studies report no dependence or sedation, but long-term safety data are limited, so this is not firmly established.
No reviews yet. If you've used Selank, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.